Development and validation of an artificial intelligence-based model for diagnosing benign, borderline, and malignant adnexal masses.

  • Post category:Gynecologic Cancer
  • Reading time:2 mins read

Journal: NPJ precision oncology

This study reports the development and validation of an artificial intelligence model, Clinical-Ovarian Multi-Task Attention (Clinical-OMTA), to classify adnexal masses as benign, borderline, or malignant using ultrasound images plus age and CA125.

Key points:

  • Model design:
  • Dual-backbone architecture: one branch for benign vs non-benign, another for borderline vs malignant.
  • Inputs: ultrasound images, patient age, and CA125, aiming for three-class classification.
  • Data and setting:
  • Retrospective multicenter cohort from 23 hospitals.
  • 1882 patients used for training/validation/internal testing from 21 centers.
  • External testing on two independent cohorts (340 and 159 patients).
  • Diagnostic performance:
  • On external datasets, Clinical-OMTA achieved AUCs comparable to ADNEX and accuracy comparable to expert subjective assessment.
  • However, adding age and CA125 did not improve performance over an image-only version (OMTA), indicating minimal incremental value of these clinical variables for the model.
  • Generalisability:
  • Performance remained stable across different ultrasound acquisition modes, scanners, scanning methods, and institutions, with accuracy in the ~80–88% range.
  • Clinical impact:
  • When used as a decision support tool, Clinical-OMTA substantially improved radiologists’ inter-reader agreement and diagnostic accuracy.
  • The authors suggest particular value in settings with limited access to expert ultrasound examiners, such as low-resource or remote environments.

Overall, this work supports AI-based adnexal mass classification as a robust and generalisable tool that can match expert performance and enhance diagnostic consistency, though multimodal (image + clinical) input did not surpass image-only modeling in this setting.

Leave a Reply